• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.用于传染病检测的分子方法和平台:FDA 批准和清除的检测方法综述。
J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25.
2
Strengths and weaknesses of FDA-approved/cleared diagnostic devices for the molecular detection of respiratory pathogens.用于呼吸道病原体分子检测的获得 FDA 批准/许可的诊断设备的优缺点。
Clin Infect Dis. 2011 May;52 Suppl 4(Suppl 4):S312-25. doi: 10.1093/cid/cir046.
3
Validation of laboratory-developed molecular assays for infectious diseases.传染病的实验室研发分子检测的验证。
Clin Microbiol Rev. 2010 Jul;23(3):550-76. doi: 10.1128/CMR.00074-09.
4
Rapid diagnostic tests for infectious diseases in the emergency department.急诊科感染性疾病的快速诊断检测。
Clin Microbiol Infect. 2021 Feb;27(2):182-191. doi: 10.1016/j.cmi.2020.02.024. Epub 2020 Feb 29.
5
FDA perspectives on diagnostic device clinical studies for respiratory infections.美国食品和药物管理局对呼吸道感染诊断设备临床研究的看法。
Clin Infect Dis. 2011 May;52 Suppl 4(Suppl 4):S305-11. doi: 10.1093/cid/cir056.
6
A review of the FDA-approved molecular testing platforms for human papillomavirus.美国食品药品监督管理局(FDA)批准的用于人乳头瘤病毒的分子检测平台综述。
J Am Soc Cytopathol. 2019 Sep-Oct;8(5):284-292. doi: 10.1016/j.jasc.2019.06.001. Epub 2019 Jun 13.
7
Companion and complementary diagnostics for infectious diseases.传染病的伴随诊断和补充诊断
Expert Rev Mol Diagn. 2020 Jun;20(6):619-636. doi: 10.1080/14737159.2020.1724784. Epub 2020 Feb 13.
8
Role of molecular diagnostics in the management of infectious disease emergencies.分子诊断在传染病突发事件管理中的作用。
Med Clin North Am. 2012 Nov;96(6):1067-78. doi: 10.1016/j.mcna.2012.08.005. Epub 2012 Sep 27.
9
Understanding, Verifying, and Implementing Emergency Use Authorization Molecular Diagnostics for the Detection of SARS-CoV-2 RNA.理解、验证和实施用于检测严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核糖核酸的紧急使用授权分子诊断方法。
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.00796-20.
10
Demise of Polymerase Chain Reaction/Electrospray Ionization-Mass Spectrometry as an Infectious Diseases Diagnostic Tool.聚合酶链反应/电喷雾电离-质谱作为传染病诊断工具的消亡。
Clin Infect Dis. 2018 Jan 18;66(3):452-455. doi: 10.1093/cid/cix743.

引用本文的文献

1
A De Novo Luciferase Bioconjugate for the Cas13-Based Detection of Influenza A.一种用于基于Cas13的甲型流感病毒检测的新型荧光素酶生物共轭物。
JACS Au. 2025 Jul 28;5(8):3914-3925. doi: 10.1021/jacsau.5c00576. eCollection 2025 Aug 25.
2
Rapid Amplification and Detection of Single-Stranded Nucleic Acids for Point-of-Care Diagnosis.用于即时诊断的单链核酸的快速扩增与检测
Small Methods. 2025 Jun;9(6):e2401733. doi: 10.1002/smtd.202401733. Epub 2025 Jan 6.
3
FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.FDA 的拟议规则及其对美国新出现和再现的被忽视热带病的监管影响。
PLoS Negl Trop Dis. 2024 May 9;18(5):e0012116. doi: 10.1371/journal.pntd.0012116. eCollection 2024 May.
4
Clinical Applications of Quantitative Real-Time PCR in Virology.定量实时聚合酶链反应在病毒学中的临床应用
Methods Microbiol. 2015;42:161-197. doi: 10.1016/bs.mim.2015.04.005. Epub 2015 Jul 7.
5
Bioluminescent Intercalating Dyes for Ratiometric Nucleic Acid Detection.用于比率型核酸检测的生物发光嵌入染料。
ACS Chem Biol. 2024 Feb 16;19(2):575-583. doi: 10.1021/acschembio.3c00755. Epub 2024 Feb 5.
6
S9.6-based hybrid capture immunoassay for pathogen detection.基于 S9.6 的杂交捕获免疫分析用于病原体检测。
Sci Rep. 2023 Dec 19;13(1):22562. doi: 10.1038/s41598-023-49881-w.
7
CRISPR‑based diagnostic approaches: Implications for rapid management of future pandemics (Review).基于 CRISPR 的诊断方法:对未来大流行快速管理的影响(综述)。
Mol Med Rep. 2023 Jun;27(6). doi: 10.3892/mmr.2023.13005. Epub 2023 May 5.
8
SARS-CoV-2 Continuous Genetic Divergence and Changes in Multiplex RT-PCR Detection Pattern on Positive Retesting Median 150 Days after Initial Infection.SARS-CoV-2 连续遗传变异与初次感染后 150 天阳性复测中多重 RT-PCR 检测模式的变化。
Int J Mol Sci. 2022 Jun 2;23(11):6254. doi: 10.3390/ijms23116254.
9
Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants.基于简化 Cas13 的检测方法可快速鉴定 SARS-CoV-2 及其变体。
Nat Biomed Eng. 2022 Aug;6(8):932-943. doi: 10.1038/s41551-022-00889-z. Epub 2022 May 30.
10
Consolidating and Upscaling Molecular Research Capacity in Nigeria: On Who's Account?巩固和提升尼日利亚的分子研究能力:究竟为了谁?
Front Res Metr Anal. 2022 Jan 5;6:788673. doi: 10.3389/frma.2021.788673. eCollection 2021.

本文引用的文献

1
A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study.基于人群的临床试验比较了应用杂交捕获 2 技术和 Cervista 检测子宫颈高危型 HPV 在 SHENCCAST II 研究中的效果。
Am J Clin Pathol. 2011 May;135(5):790-5. doi: 10.1309/AJCPKA6ATAPBZ6JQ.
2
Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.预防围产期 B 型链球菌病——美国疾病预防控制中心 2010 年修订指南。
MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36.
3
Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach.采用新型双重靶标方法提高 COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0 检测 HIV-1 RNA 的定量能力。
J Clin Virol. 2010 Sep;49(1):41-6. doi: 10.1016/j.jcv.2010.06.004. Epub 2010 Jul 15.
4
Validation of laboratory-developed molecular assays for infectious diseases.传染病的实验室研发分子检测的验证。
Clin Microbiol Rev. 2010 Jul;23(3):550-76. doi: 10.1128/CMR.00074-09.
5
Performance of the Aptima HIV-1 RNA qualitative assay with 16- and 32-member specimen pools.16 成员和 32 成员标本池的 Aptima HIV-1 RNA 定性检测的性能。
J Clin Microbiol. 2010 Sep;48(9):3343-5. doi: 10.1128/JCM.01030-10. Epub 2010 Jun 30.
6
Multicenter evaluation of the LightCycler methicillin-resistant Staphylococcus aureus (MRSA) advanced test as a rapid method for detection of MRSA in nasal surveillance swabs.多中心评估 LightCycler 耐甲氧西林金黄色葡萄球菌(MRSA)高级检测试验作为一种快速检测鼻拭子中 MRSA 的方法。
J Clin Microbiol. 2010 May;48(5):1661-6. doi: 10.1128/JCM.00003-10. Epub 2010 Mar 24.
7
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).艰难梭菌感染临床实践指南:美国医疗保健流行病学学会(SHEA)和美国传染病学会(IDSA)2010 年更新版。
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55. doi: 10.1086/651706.
8
Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C.综述文章:快速病毒学应答在确定慢性丙型肝炎治疗持续时间中的作用。
Aliment Pharmacol Ther. 2010 Jun;31(12):1251-67. doi: 10.1111/j.1365-2036.2010.04300.x. Epub 2010 Mar 17.
9
Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay.罗氏 Cobas AmpliPrep/Cobas TaqMan 检测法第二版对人类免疫缺陷病毒 1 载量低估的校正。
J Clin Microbiol. 2010 Apr;48(4):1337-42. doi: 10.1128/JCM.01226-09. Epub 2010 Feb 17.
10
ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.ARTISTIC 试验:人乳头瘤病毒(HPV)检测在宫颈癌初筛中的应用
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv. doi: 10.3310/hta13510.

用于传染病检测的分子方法和平台:FDA 批准和清除的检测方法综述。

Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.

机构信息

Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA.

出版信息

J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25.

DOI:10.1016/j.jmoldx.2011.05.011
PMID:21871973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3194051/
Abstract

The superior sensitivity and specificity associated with the use of molecular assays has greatly improved the field of infectious disease diagnostics by providing clinicians with results that are both accurate and rapidly obtained. Herein, we review molecularly based infectious disease diagnostic tests that are Food and Drug Administration approved or cleared and commercially available in the United States as of December 31, 2010. We describe specific assays and their performance, as stated in the Food and Drug Administration's Summary of Safety and Effectiveness Data or the Office of In Vitro Diagnostic Device Evaluation and Safety's decision summaries, product inserts, or peer-reviewed literature. We summarize indications for testing, limitations, and challenges related to implementation in a clinical laboratory setting for a wide variety of common pathogens. The information presented in this review will be particularly useful for laboratories that plan to implement or expand their molecular offerings in the near term.

摘要

分子检测的高灵敏度和特异性极大地提高了传染病诊断领域的水平,为临床医生提供了准确、快速的检测结果。本文回顾了截至 2010 年 12 月 31 日,美国食品药品监督管理局(FDA)批准或通过的、商业化的基于分子的传染病诊断检测方法。我们描述了特定的检测方法及其性能,依据来自 FDA 的安全性和有效性数据概要,或体外诊断设备评估和安全办公室的决策总结、产品说明书,或同行评议文献。我们总结了针对各种常见病原体的检测指征、局限性和在临床实验室实施的相关挑战。本文所提供的信息对那些计划在近期内实施或扩展其分子检测的实验室尤其有用。